Interferon-γ-induced MHC class I expression and defects in Jak/Stat signalling in methylcholanthrene-induced sarcomas

Scandinavian Journal of Immunology

Volumn 46, Issue 4, 1997, Pages 379-387

  Svane, I M ^a   Engel, A M ^a   Nielsen, M ^a   Werdelin, O ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLCHOLANTHRENE; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PHOSPHOTRANSFERASE; STAT1 PROTEIN; TRANSCRIPTION FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; FEMALE; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SARCOMA; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE; TUMOR GROWTH;

EID: 0030879172     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.1997.d01-141.x     Document Type: Article

References (53)

1. Tanaka K, Yoshioka T, Biberich C, Jay G. Role of the major histocompatibility complex class I antigens in tumor growth and metastasis. Annu Rev Immunol 1988;6:359-80.
2. Wallich R, Bulbuc N, Hämmerling C, Katzav S, Segal S, Feldman M. Abrogation of metastatic properties of tumour cells by de novo expression of H-2K antigens following H-2 gene transfection. Nature 1985;315:301-5.
3. Plaksin D, Gelber C, Feldman M, Eisenbach L. Reversal of the metastatic phenotype in Lewis lung carcinoma cells after transfection with syngeneic H-2 Kb gene. Proc Natl Acad Sci USA 1988;85:4463-7.
4. Austin FC, Finerty JF, Sogn JA. Cancer immunology: highlights of the NCI extramural immunology program. Cancer Invest 1990;8:207-28.
5. Elliott BE, Carlow DA, Rodricks A, Wade A. Perspectives on the role of MHC antigens in normal and malignant cell development. Adv Cancer Res 1989;53:181-245.
6. Garrido F, Ruiz-Cabello F. MHC expression on human tumors - its relevance for local tumor growth and metastasis. Sem Cancer Biol 1991;2:3-10.
7. Schmidt W, Festenstein H. Resistance to cell mediated cytotoxicity is correlated with reduction of H-2K gene products in AKR leukemia. Immunogenetics 1982;16:257-67.
8. Garrido F, Cabrera T, Lopez-Nevot MA, Ruiz-Cabello F. HLA class 1 antigens in human tumors. Adv Cancer Res 1996;67:155-95.
9. Hui KM, Kim BS. Tumor specific immunity induced by somatic hybrids. Cell Immunol 1984;87:591-600.
10. Höglund P, Ljunggren HG, Kärre K, Jay G. Role of major histocompatibilily complex class I molecules in tumor rejection. New insights from studies with synthetic peptides and transgenic mice. Immunol Res 1990;9:298-313.
11. Weber JS, Jay G, Tanaka K, Rosenberg SA. Immunotherapy of a murine tumor with interleukin 2. Increased sensitivity after MHC class I gene transfection. J Exp Med 1987;166:1716-33.
12. Christinck ER, Luscher MA, Barber BH, Williams DB. Peptide binding to class I MHC on living cells and quantitation of complexes required for CTL lysis. Nature 1991;352:67-70.
13. Wallny H, Deres K, Faath S et al. Identification and quantification of a naturally presented peptide as recognized by cytotoxic T lymphocytes specific for an immunogenic tumor variant. Int Immunol 1992;4:1085-90.
14. Kageyama S, Tsomides TJ, Sykulev Y, Eisen HN. Variations in the number of peptide MHC class I complexes required to activate cytotoxic T cell responses. J Immunol 1995;154:567-76.
15. Browning M, Bodmer WF. MHC antigens and cancer: implications for T-cell surveillance. Curr Opin Immunol 1992;4:613-18.
16. Cohen EP, Kim TS. Neoplastic cells that express low levels of MHC class 1 determinants escape host immunity. Sem Cancer Biol 1994;5:419-28.
17. Klein G. Immune and non-immune control of neoplastic development: Contrasting effects of host and tumour evolution. Cancer 1980;45:2486-524.
18. Lopez-Nevot MA, Esteban F, Ferron A et al. HLA class I gene expression on human primary tumors and autologous metastases: demonstration of selective losses of HLA antigens on colorectal, gastric and laryngeal carcinomas. Br J Cancer 1989;59:221-6.
19. McDougall CJ, Ngoi SS, Goldman, I et al. Reduced expression of HLA class I and class II antigens in colon cancer. Cancer Res 1990;50:8023-7.
20. Garrido F, Carara T, Concha A, Glew S, Ruiz-Cabello F, Stern PL. Natural history of HLA expression during tumor development. Immunol Today 1993;14:491-9.
21. Engel A, Svane IM, Mouritsen S, Rygaard J, Clausen J, Werdelin O. Methylcholanthrene-induced sarcomas in nude mice have short induction times and relatively low levels of surface MHC class I expression. APMIS 1996;104:629-39.
22. Svane IM, Engel A, Nielsen M, Ljunggren H, Rygaard J, Werdelin O. Chemically induced sarcomas from nude mice are more immunogenic than similar sarcomas from congenic normal mice. Eur J Immunol 1996;26:1844-50.
23. Bosnia GC, Custer RP, Bosma MJ. A severe combined immunodeficiency mutation in the mouse. Nature 1983;301:527-30.
24. Engel A, Svane IM, Rygaard J, Werdelin O. MCA-sarcomas induced in scid mice are more immunogenic than MCA sarcomas induced in congenic, immunocompetent mice. Scand J Immunol 1997;45:463-70.
25. Thomson A. The Cytokine Handbook. 2nd Edn. San Diego: Academic Press, 1994.
26. Knop J. Immunologic effects of interferon. J Invest Dermatol 1990;95:72S-4S.
27. + tumor infiltrating lymphocytes. J Exp Med 1991;173:647-58.
28. Kohonen-Corish MRJ, King NJC, Woodhams CE, Ramshaw IA. Immunodeficient mice recover from infection with vaccinia virus expressing interferon gamma. Eur J Immunol 1990;20:157-61.
29. Dalton DK, Pius-Meek S, Keshav S, Figari IS, Bradley A, Stewart TA. Multiple defects of immune cell function in mice with disrupted interferon gamma genes. Science 1993;259:1739-42.
30. Restifo NP, Esquivel F, Kawakami Y et al. Identification of human cancers deficient in antigen processing. J Exp Med 1993;177:265-72.
31. Aki M, Shimbara N, Takashina M et al. Interferon gamma induces different subunit organizations and functional diversity of proteasomes. J Biochem 1994;115:257-69.
32. Klar D, Hämmerling G. Induction of assembly of MHC class I heavy chains with beta-2 microglobulin by interferon gamma. EMBO J 1989;8:475-81.
33. Anderson SL, Shen T, Lou J et al. The endoplasmic reticular heat shock protein gp96 is transcriptionally up-regulated in interferon-treated cells. J Exp Med 1994;180:1565-9.
34. Farrar MA, Schreiber RD. The molecular cell biology of interferon gamma and its receptor. Annu Rev Immunol 1993;11:571-611.
35. Silvennoinen O, Inle JN, Schlessinger J, Levy D. Interferon induced nuclear signalling by Jak protein tyrosine kinases. Nature 1993;366:583-7.
36. Resnitzaky D, Tiefenbrun N, Berissi H, Kimchi A. Interferons and interleukin 6 suppress phosphorylation of the retinoblastoma protein in growth-sensitive hematopoietic cells. Proc Natl Acad Sci USA 1992;89:402-6.
37. Shuai K, Horvath CM, Huang LHT, Qureshi SA, Cowburn D, Darnell JE. Interferon activation of the transcription factor stat 91 involves dimerization through SH2-phosphotyrosyl peptide interactions. Cell 1994;76:821-8.
38. Pellegrini S, Schindler C. Early events in signalling by interferons. TIBS 1993;18:338-42.
39. Bartlett GL. Effect of host immunity on the antigenic strength of primary tumors. J Natl Cancer Inst 1972;49:493-504.
40. LeClaire RD, Basu M, Pinson DM et al. Characterization and use of monoclonal and polyclonal antibodies against the mouse IFN gamma receptor. J Leuc Biol 1992;51:507-16.
41. Nielsen M, Svejgaard A, Skov S, Ødum N. Interleukin 2 induced tyrosine phosphorylation and nuclear translocation of stat 3 in human T lymphocytes. Eur J Immunol 1994;24:3082-6.
42. Dustin ML, Rothlein R, Bhan AK, Dinarello CA, Springer TA. Induction by IL 1 and interferon gamma: tissue distribution, biochemistry and function of a natural adherence molecule (ICAM-1). J Immunol 1986;137:245-54.
43. Briscoe J, Rogers NC, Witthuhn BA et al. Kinase-negative mutants of JAK1 can sustain interferon gamma inducible gene expression but not an antivrial state. EMBO J 1996;15:799-809.
44. + T cells against the wild-type tumor: Correlation with antigen presentation capability. J Exp Med 1992;175:1423-31.
45. Roth C, Rochlitz C, Kourilsky P. Immune response against tumors. Adv Immunol 1994;57:281-351.
46. Porgador A, Bannerji R, Watanabe Y, Feldman M, Gilboa E, Eisenbach L. Antimetastatic vaccination of tumor-bearing mice with two types of IFN gamma gene-inserted tumor cells. J Immunol 1993;150:1458-70.
47. Engel A-M, Svane IM, Madsen MW, Pedersen M, Werdelin O. Molecular aberrations in the MHC class I-restricted pathway for antigen presentation in methylcholanthrene sarcomas from nude mice: discrepancies between MHC mRNA and surface protein. Clin Exp Immunol 1997; 109: (in press).
48. Xu B, Grander D, Sangfelt O, Einhorn S. Primary leukemia cells resistant to alpha interferon in vitro are defective in the activation of the DNA-binding factor interferon stimulated gene factor 3. Blood 1994;84:1942-9.
49. Durbin JE, Hackenmiller R, Simon MC, Levy DE. Targeted disruption of the mouse STAT1 gene results in compromised innate immunity to viral disease. Cell 1996;84:443-50.
50. Lai KS, Jin Y, Graham DK, Witthuhn BA, Ihle JN, Liu ET. A kinase-deficient splice variant of the human JAK3 is expressed in hematopoietic and epithelial cancer cells. J Biol Chem 1995;270:25028-36.
51. Boulton TG, Zhong Z, Wen Z, Darnell JE, Stahl N, Yancopoulos GD. STAT3 activation by cytokines utilizing gp130 and related tranducers involves a secondary modification requiring an H7-sensitive kinase. Proc Natl Acad Sci USA 1995;92:6915-19.
52. Migone T, Lin J, Cereseto A et al. Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-1. Science 1995;269:79-81.
53. Nielsen M, Kaltoft K, Nordahl M, Röpke C, Geisler C, Mustelin T, Dobson P, Svejgaard A, Ødum N. Constitutive activation of a slowly migrating isoform of Stat3 in mucosis fungoides: Tyrphostin AG490 inhibits Stat3 activation and growth of mucosis fungoides tumor cell lines. Proc Natl Acad Sci USA 1997;94:6767-9.